磁共振成像
正电子发射断层摄影术
分子成像
药物输送
细胞外基质
癌症研究
翻译(生物学)
医学
肿瘤微环境
纳米技术
免疫系统
靶向给药
细胞外
神经科学
医学影像学
荧光寿命成像显微镜
化学
细胞生物学
分子探针
功能磁共振成像
临床前影像学
多路复用
生物物理学
药品
五肽重复序列
转化研究
材料科学
内化
共轭体系
肿瘤细胞
免疫疗法
作者
Ibrahim Iddi Juku,Liangda Xing,Ya Li,Fangfang Wei,Mingliang Zhu,Xian Li,邓新荣,Fan Xu,Shihan Deng,Yinnong Jia
出处
期刊:
[Elsevier BV]
日期:2026-11-01
卷期号:: 100064-100064
标识
DOI:10.1016/j.tmed.2026.100064
摘要
The tumor microenvironment (TME) impairs drug delivery and immune clearance through aberrant fibrin deposition, dense extracellular matrix and dysfunctional vasculature. Cys-Arg-Glu-Lys-Ala (CREKA), a pentapeptide tumor-homing ligand, binds fibrin-fibronectin complexes overexpressed in the tumor stroma. Unlike conventional peptides targeting cell-surface receptors, which are frequently downregulated in advanced tumors, CREKA engages stable extracellular components, sidestepping receptor-expression heterogeneity and offering greater selectivity than passive delivery alone. This review integrates three threads usually treated separately: the molecular basis of CREKA binding, its self-amplifying tumor accumulation, and the breadth of preclinical delivery and imaging platforms. We examine CREKA conjugated to liposomes, polymeric nanoparticles, iron oxide nanoparticles, carbon nanotubes and siRNA carriers, with reported tumor enrichment of up to about 6-fold over non-targeted controls in individual studies. Incorporated into magnetic resonance imaging (MRI), positron emission tomography (PET) and near-infrared platforms, preclinical CREKA probes have visualized 0.4-0.5 mm metastases, below conventional detection limits. We further assess its electrostatic binding, self-amplification through localized clot formation, and synergy with photothermal, magnetic and immunotherapeutic strategies. Critically, fibrin-fibronectin targets are not tumor-exclusive, a key translational limitation. Together, these findings establish CREKA-based theranostics as a promising preclinical strategy uniting molecular imaging with targeted therapy on one platform.
科研通智能强力驱动
Strongly Powered by AbleSci AI